The goal of this project is to develop a microfluidics chip-based test for stratification of COVID-19 patients in risk for severe complications based on early detected coagulation and extracellular vesicles (EVs) disbalances. Aims of the project: 1. To develop and fabricate microfluidics chip for purification and detection of procoagulant EVs. 2. To validate EVs-microfluidics chip using fluorescent size-beads, plasma from healthy donors and different sets of antibodies. 3. To characterize the coagulation imbalances in COVID-19 patients using microfluidics EVs chip with procoagulant antibodies in parallel with conventional coagulometer and thrombodynamics analyzer. The coronavirus disease of 2019 (COVID-2019) is a viral infection caused by virus SARS-CoV2 from the beta-coronavirus group. With six million cases of COVID-19 in the world and almost 360,000 deaths, a global epidemics of COVID-19 is affecting health and economic situation worldwide. In Kazakhstan, due to the government quarantine measures, the impact of COVID-19 epidemics was not that severe as in other countries with app 9,500 confirmed positive cases and 37 deaths. However, the growth of positive cases continues, and according to WHO, the world will face a second wave of coronavirus by the end of this year.